Medical Castration With LHRH Agonists: 25 Years Later With Major Benefits Achieved on Survival in Prostate Cancer
Bibliographic record
Abstract
Prostate cancer is the most frequently diagnosed cancer and the second cause of cancer death in men in North America (Jemal et al, 2003).In fact, one of eight men will be diagnosed with prostate cancer during his lifetime.At such a rate, prostate cancer will kill more than 3 000 000 men among the male population presently living in the United States, whereas more than 200 000 men die annually worldwide from prostate cancer.The medical and social consequences of this disease are comparable to those of breast cancer in women.Prostate cancer is thus a major challenge in urgent need of significant improvement in diagnosis and treatment. Limitations of Surgical Castration and High Doses of EstrogensAlthough it is known today that surgical castration and high-dose estrogen (monotherapy) discovered by Huggins (Huggins and Hodges, 1941) is limited to blockade of the androgens of testicular origin, a long series of reports has shown that such treatment achieves a positive response in as many as 60% to 70% of advanced prostate cancer patients, although for a limited period of time (Nesbit and Baum, 1950;Staubitz et al, 1954;VACURG, 1967;Mettlin et al, 1982;Murphy et al, 1983).As indicated by such a high proportion of positive responses observed after only partial blockade of androgens, prostate cancer is highly sensitive to endocrine therapy.In fact, prostate cancer is the most sensitive of all hormone-sensitive cancers to endocrine therapy.The serious and frequently lethal cardiovascular and
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.001 | 0.002 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".